-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written byWang Cong
EditorWang Duoyu TypesettingShui Chengwen Recently, the new subtypes BQ and XBB of the new coronavirus Omicron
mutant strain are spreading
rapidly.
This may be due to their additional mutations in the spike protein, resulting in a stronger ability to escape neutralizing antibodies produced by vaccination
.
Omicron has been the dominant circulating strain worldwide since last winter, with BA.
5, a highly contagious subtype of Omicron, which caused a large number of new cases
this summer and fall.
Approximately 68% of recent new COVID-19 cases in the United States have been caused
by two new Omicron subtypes, BQ.
1 or BQ.
1.
1.
In Asian countries, including Singapore, Bangladesh and India, the new Omicron subtype XBB is setting off a new wave
of infections.
On December 13, 2022, the team of He Dayi of Columbia University in the United States published a report in the journal Cell entitled: Alarming antibody evasion properties of rising Research paper by SARS-CoV-2 BQ and XBB subvariants.
The study confirmed that the Omicron subtypes, BQ.
1, BQ.
1.
1, XBB, and XBB.
1, have the strongest known ability to escape neutralizing antibodies, and therefore, they May dominate the population because of its dominance in escape-neutralizing antibodies and become the new dominant circulating strain
.
The core mutation sites
of BQ and XBB This study showed that the new crown vaccine and infected people's serum had a high impact on BQ.
1, BQ.
1.
1, XBB and The neutralizing capacity of XBB.
1 was significantly reduced, including serum
from WA1/BA.
5 bivalent mRNA vaccine-fortified individuals.
The neutralization titers for BQ and XBB were reduced by a factor of 13-81 and 66-155, respectively, which far exceeded the situation
with any previously observed COVID mutant strains.
Monoclonal antibodies that can neutralize early Omicron are basically ineffective
against these Omicron subtypes.
Overall, the results of this study suggest that Omicron BQ and XBB pose a serious threat to current COVID vaccines, including bivalent mRNA vaccines against mutant strains.
And all current therapeutic monoclonal antibodies are also ineffective
against them.
Therefore, BQ and XBB may dominate the population because of their dominance in escape-neutralizing antibodies and become the new dominant epidemic strains
.
He Dayi
was born on November 3, 1952 in Taiwan, China, and immigrated to Los Angeles, California with his family at the age of 12
.
In 1970, He was admitted to the Massachusetts Institute of Technology in the United States, and graduated with first honors four years later, and then received his doctorate
in medicine from Harvard University.
On June 5, 1981, the US Centers for Disease Control and Prevention released five AIDS case reports, which was also the first time AIDS was detected in the world
.
At this time, He Dayi was working as an intern at Sinai Medical Center, and he came into contact with this first batch of AIDS cases
.
Since then, He Dayi has devoted himself to AIDS research, becoming one of the first scientists in the world to recognize that AIDS is caused by the virus, and one of
the first scientists to elucidate the diversity of HIV replication.
In 1996, in the face of the frequent drug resistance problems of AIDS patients, He Dayi proposed "cocktail therapy", which combines a variety of anti-AIDS drugs into a combination, combining protease inhibitor drugs with nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitor drugs, which can treat AIDS more effectively than a single drug and is less prone to drug resistance
.
Since its use in 1996, cocktail therapy has effectively reduced the mortality rate of AIDS patients and is still one of
the most commonly used and effective AIDS treatments.
For his outstanding contribution to AIDS treatment by "cocktail therapy", He Dayi was selected as Time magazine's Person of the Year in 1996, and in 2010, he was called "The Man Who Defeated AIDS"
by Time magazine.
Paper link:
Open reprint, welcome to forward to Moments and WeChat groups
EditorWang Duoyu TypesettingShui Chengwen Recently, the new subtypes BQ and XBB of the new coronavirus Omicron
mutant strain are spreading
rapidly.
This may be due to their additional mutations in the spike protein, resulting in a stronger ability to escape neutralizing antibodies produced by vaccination
.
Omicron has been the dominant circulating strain worldwide since last winter, with BA.
5, a highly contagious subtype of Omicron, which caused a large number of new cases
this summer and fall.
Approximately 68% of recent new COVID-19 cases in the United States have been caused
by two new Omicron subtypes, BQ.
1 or BQ.
1.
1.
In Asian countries, including Singapore, Bangladesh and India, the new Omicron subtype XBB is setting off a new wave
of infections.
On December 13, 2022, the team of He Dayi of Columbia University in the United States published a report in the journal Cell entitled: Alarming antibody evasion properties of rising Research paper by SARS-CoV-2 BQ and XBB subvariants.
The study confirmed that the Omicron subtypes, BQ.
1, BQ.
1.
1, XBB, and XBB.
1, have the strongest known ability to escape neutralizing antibodies, and therefore, they May dominate the population because of its dominance in escape-neutralizing antibodies and become the new dominant circulating strain
.
The core mutation sites
of BQ and XBB This study showed that the new crown vaccine and infected people's serum had a high impact on BQ.
1, BQ.
1.
1, XBB and The neutralizing capacity of XBB.
1 was significantly reduced, including serum
from WA1/BA.
5 bivalent mRNA vaccine-fortified individuals.
The neutralization titers for BQ and XBB were reduced by a factor of 13-81 and 66-155, respectively, which far exceeded the situation
with any previously observed COVID mutant strains.
Monoclonal antibodies that can neutralize early Omicron are basically ineffective
against these Omicron subtypes.
Overall, the results of this study suggest that Omicron BQ and XBB pose a serious threat to current COVID vaccines, including bivalent mRNA vaccines against mutant strains.
And all current therapeutic monoclonal antibodies are also ineffective
against them.
Therefore, BQ and XBB may dominate the population because of their dominance in escape-neutralizing antibodies and become the new dominant epidemic strains
.
He Dayi
was born on November 3, 1952 in Taiwan, China, and immigrated to Los Angeles, California with his family at the age of 12
.
In 1970, He was admitted to the Massachusetts Institute of Technology in the United States, and graduated with first honors four years later, and then received his doctorate
in medicine from Harvard University.
On June 5, 1981, the US Centers for Disease Control and Prevention released five AIDS case reports, which was also the first time AIDS was detected in the world
.
At this time, He Dayi was working as an intern at Sinai Medical Center, and he came into contact with this first batch of AIDS cases
.
Since then, He Dayi has devoted himself to AIDS research, becoming one of the first scientists in the world to recognize that AIDS is caused by the virus, and one of
the first scientists to elucidate the diversity of HIV replication.
In 1996, in the face of the frequent drug resistance problems of AIDS patients, He Dayi proposed "cocktail therapy", which combines a variety of anti-AIDS drugs into a combination, combining protease inhibitor drugs with nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitor drugs, which can treat AIDS more effectively than a single drug and is less prone to drug resistance
.
Since its use in 1996, cocktail therapy has effectively reduced the mortality rate of AIDS patients and is still one of
the most commonly used and effective AIDS treatments.
For his outstanding contribution to AIDS treatment by "cocktail therapy", He Dayi was selected as Time magazine's Person of the Year in 1996, and in 2010, he was called "The Man Who Defeated AIDS"
by Time magazine.
Paper link:
https://doi.
org/10.
1016/j.
cell.
2022.
12.
018
Open reprint, welcome to forward to Moments and WeChat groups
